NEWBEAT biomarker data
收藏Mendeley Data2026-04-09 收录
下载链接：
https://data.mendeley.com/datasets/kfwz4s83zp/1
下载链接
链接失效反馈官方服务：
资源简介：
NEWBEAT was a phase 2, multicenter, single-arm trial that sought to evaluate the efficacy and safety of first-line triple therapy comprising nivolumab, bevacizumab, and paclitaxel in patients with HER2-negative advanced metastatic or inoperable recurrent BC. The purpose of the accompanying biomarker study (WJOG9917BTR) was to explore potential biomarkers of the efficacy and toxicity of triple therapy in patients with HER2-negative mBC.
提供机构：
Yukinori Ozaki
